Transcatheter arterial chemoembolization with a fine-powder formulation of cisplatin for hepatocellular carcinoma

Abstract

We conclude that TACE using a suspension of DDPH in LPD could be a useful treatment for HCC.

Efficacy and safety of cisplatin versus miriplatin in transcatheter arterial chemoembolization and transarterial infusion chemotherapy for hepatocellular carcinoma: A randomized controlled trial

“…When comparing cisplatin and doxorubicin, the objective early response rates were 50% and 24%, the median progression-free survival time was 8.6 and 3.0 months, and the overall survival rates at 1 and 2 years were 81.0% and 76.0%, and 68.0% and 46.0%, respectively. 24 The response rates of cisplatin and epirubicin were 62.5% and 51.5%, and the overall survival rates at 1 and 2 years were 88.5% and 71.8%, and 83.0% and 57.9%, respectively. 21,26 According to these studies, cisplatin showed a significantly higher response rate, better progression-free survival and better overall survival than the anthracycline agents.…”

“…Twelve articles (two systematic reviews, seven retrospective studies, one historical cohort study, one prospective study and one randomized phase II trial) compared the response rates and survival between cisplatin or miriplatin and other drugs. When comparing cisplatin and doxorubicin, the objective early response rates were 50% and 24%, the median progression‐free survival time was 8.6 and 3.0 months, and the overall survival rates at 1 and 2 years were 81.0% and 76.0%, and 68.0% and 46.0%, respectively . The response rates of cisplatin and epirubicin were 62.5% and 51.5%, and the overall survival rates at 1 and 2 years were 88.5% and 71.8%, and 83.0% and 57.9%, respectively .…”

“…T HE ANTICANCER AGENTS often used with TACE and TAI are the anthracycline agents epirubicin and doxorubicin and the platinum-containing agents cisplatin and miriplatin. Twelve articles (two systematic reviews, 2,19 seven retrospective studies, 14,[20][21][22][23][24][25] one historical cohort study, 26 one prospective study 27 and one randomized phase II trial) 12 compared the response rates and survival between cisplatin or miriplatin and other drugs. When comparing cisplatin and doxorubicin, the objective early response rates were 50% and 24%, the median progression-free survival time was 8.6 and 3.0 months, and the overall survival rates at 1 and 2 years were 81.0% and 76.0%, and 68.0% and 46.0%, respectively.…”

Transcatheter Arterial Chemoembolization Based on Hepatic Hemodynamics for Hepatocellular Carcinoma

“…As a result, suspensions show a longer anticancer drug release time at the tumor border and higher continuous drug concentrations. The longer tissue drug activity period associated with the use of suspensions produces superior antitumor effects, as evaluated by the growth ratio and the results of histopathological investigations [16, 17, 23, 24]. Some problems exist, however.…”

Treatment Strategy for Recurrent Multiple Hepatocellular Carcinoma

“…TACE is primarily per- formed as chemolipiodolization, using anticancer drugs mixed with lipiodol [8,9]. There have been several retrospective reports of TACE with anthracyclines versus platinum compounds, suggesting the usefulness of platinum compounds [10,11] [15]. Disease had advanced after previous TACE with epirubicin in 59% of patients.…”